Sperogenix Therapeutics Limited Homepage | 曙方医药集团北京罕友医药有限公司官方网站

GET TO KNOW US

KNOW

About us

Sperogenix is a business platform concentrating on rare disease products commercialization in China. Sperogenix focuses on clinical stage and commercialize stage development of orphan drugs, dedicate to establishing innovative business model complying with the characteristics of rare diseases market in China, promoting linkage and cooperation among stakeholders, providing affordable and reliable products and services for patients and physicians, bringing benefit to millions of rare diseases patients in China.

Vision, Mission & Values

Vision

Strive to become the respected leading rare diseases company with commercial success in China

Mission

Committed to providing advanced products and solutions for Chinese rare diseases patients, narrowing the gap between China and developed countries and regions in diagnosis and treatment, and meeting the unmet medical needs in the field of rare diseases in China.

Values

Patients and physicians centerd. High standard of responsibility and ethics. Unremitting learning and innovation

Strategies

BUSINESS DEVELOPMENT

Meet the huge unmet demands with advanced treatment

CLINICAL DEVELOPMENT

Accelerate both global and local product approval and launch

CUSTOMER ENGAGEMENT

Establish a promising future for product value maximization

Scientific Advisory Board

Hanlan LIU PhD., MBA

Khazal PARADIS MDCM

Renato SKERLJ PhD.

Executive Management

Co-Founder, Chairman & Chief Executive Officer

Co-Founder, Chief Business Officer & Chief Operating Officer

Hanlan LIU PhD., MBA

Chief Scientific Officer & Chief Development Officer

Khazal PARADIS MDCM

Chief Medical Officer

Investors

Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. LAV's vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.

Morningside Venture

Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.